Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Marlène Vonarx"'
Publikováno v:
European Journal of Dermatology. 27:86-88
Bullous drug eruptions are infrequent and potentially serious situations. Bullae are characteristic of two main diagnoses: the spectre of toxic epidermal necrolysis (TEN), the most serious, and the bullous fixed drug eruption (FDE); even if other sev
Autor:
Aurélie Jacobsoone, Annie Vermersch, Johana Béné, Anne-Fleur Tronquoy, Marlène Vonarx, Marine Auffret, Dominique Hillaire-Buys, Patrick Coupe, Samy Babai, Sophie Gautier, Marie-Josèphe Jean-Pastor
Publikováno v:
Fundamental and Clinical Pharmacology
Fundamental and Clinical Pharmacology, Wiley, 2015, 29 (1), pp.112-114. ⟨10.1111/fcp.12083⟩
Fundamental & Clinical Pharmacology
Fundamental & Clinical Pharmacology, 2015, 29 (1), pp.112-114. ⟨10.1111/fcp.12083⟩
Fundamental & Clinical Pharmacology, Wiley, 2015, 29 (1), pp.112-114. ⟨10.1111/fcp.12083⟩
Fundamental and Clinical Pharmacology, Wiley, 2015, 29 (1), pp.112-114. ⟨10.1111/fcp.12083⟩
Fundamental & Clinical Pharmacology
Fundamental & Clinical Pharmacology, 2015, 29 (1), pp.112-114. ⟨10.1111/fcp.12083⟩
Fundamental & Clinical Pharmacology, Wiley, 2015, 29 (1), pp.112-114. ⟨10.1111/fcp.12083⟩
International audience; To report three cases of bullous pemphigoid in patients treated with vildagliptin. Case 1: An 86-year-old woman presented with bullous pemphigoid after 1 month of treatment with vildagliptin and metformin. After introduction o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5048a6fbbb5a64c6f7c72ae98e61fc59
https://hal.umontpellier.fr/hal-02279576
https://hal.umontpellier.fr/hal-02279576
Publikováno v:
JAAD Case Reports
Ustekinumab, a monoclonal antibody that blocks interleukin-12 and interleukin-23, is a biological therapy used to treat moderate-to-severe psoriasis. Bullous pemphigoid (BP) induced by anti–tumor necrosis factor-alfa (TNF-α) agents has been descri
Publikováno v:
Annales de Dermatologie et de Vénéréologie. 141:S492
Introduction L’ustekinumab, anticorps monoclonal anti-IL-12 IL-23 est une biotherapie utilisee depuis 2010 dans le traitement du psoriasis modere a severe. Des cas de pemphigoides induites par les anti-TNF alpha ont ete decrites dans la litterature